Peptides and combination thereof for use in the immunotherapy against cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A composition comprising a peptide consisting of the amino acid sequence KESDGFHRF (SEQ ID NO: 229), an adjuvant, and a pharmaceutically acceptable carrier.
2. The composition of claim 1 wherein the adjuvant is selected from the group consisting of imiquimod, resiquimod, GM-CSF, interferon-alpha, interferon-beta, CpG oligonucleotides, poly-(I:C), particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
3. The composition of claim 2 , wherein the adjuvant is IL-2.
4. The composition of claim 2 , wherein the adjuvant is IL-7.
5. The composition of claim 2 , wherein the adjuvant is IL-12.
6. The composition of claim 2 , wherein the adjuvant is IL-15.
7. The composition of claim 2 , wherein the adjuvant is IL-21.
8. The composition of claim 1 , wherein the composition is a pharmaceutical composition and further comprises a buffer.
9. The composition of claim 1 , further comprising cyclophosphamide, sunitinib, bevacizumab, or sildenafil.